Efficacy of Avastin in Improving Visual Acuity and Reducing Retinal Swelling in Patients with Diabetic Retinopathy at a Hospital in Gauteng (SA)
Open Access
- 1 July 2026
- journal article
- research article
- Published by Taylor & Francis in Clinical Optometry
- Vol. ume 18, 1-5
Abstract
Background: Globally, diabetic retinopathy (DR) has been identified as the cause of blindness among adults with both Type 1 diabetes (T1DM) and Type 2 diabetes (T2DM). Purpose: The study aimed to investigate the efficacy of Avastin in improving visual acuity (VA) and reducing central foveal (CFT) and parafoveal thicknesses (PFT) in participants with DR. Patients and Methods: A cross-sectional observational study was conducted at a tertiary hospital in the Gauteng Province (South Africa). A total of 55 participants were included in the study, with VA’s that were less than 0.5 LogMAR units and CFT’s greater than 300 microns (µm). Measurements of VA’s, CFT (µm), and PFT (µm) were conducted at baseline, after three and six months of receiving Avastin treatment. Numerical data were collected and analysed using IBM SPSS Version 28, and non-parametric tests were used to compare the means of the variables. Results: The mean VA improved from 1.00± 0.71 LogMAR at baseline to 0.66± 0.51 and 0.57± 0.48 LogMAR at 3 and 6 months, respectively (p < 0.001). The mean CFT improved from 441.22± 142.35 µm at baseline to 355.58± 129.38 µm and 308.40± 137.60 µm at 3 and 6 months, respectively (p < 0.001). The superior parafoveal thickness (SPFT) showed the highest decrease from a mean baseline of 379.04 µm to a mean baseline of 317.36 µm at 3 months. At 6 months, the decrease in the NPFT was statistically significant (p < 0.025) in improving VA. Conclusion: Early administration of Avastin treatment in diabetic patients is effective in reducing the mean CFT, NPFT, and improving the mean VA.Keywords
This publication has 13 references indexed in Scilit:
- Molecular mechanism of VEGF and its role in pathological angiogenesisJournal of Cellular Biochemistry, 2022
- Management of Diabetic Macular Edema: Guidelines from the Emirates Society of OphthalmologyOphthalmology and Therapy, 2022
- Efficacy and mechanism of anti-vascular endothelial growth factor drugs for diabetic macular edema patientsWorld Journal of Diabetes, 2022
- Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045Ophthalmology, 2021
- Assessment for the Correlation Between Diabetic Retinopathy and Metabolic Syndrome: A Cross-Sectional StudyDiabetes, Metabolic Syndrome and Obesity, 2021
- The Evolving Treatment of Diabetic RetinopathyClinical Ophthalmology, 2020
- The Diabetic Retinopathy Clinical Research Network (DRCR.net) and Its Contributions to the Treatment of Diabetic RetinopathyOphthalmic Research, 2019
- Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelinesIndian Journal Of Ophthalmology, 2016
- Primary Intravitreal Bevacizumab for Diffuse Diabetic Macular EdemaOphthalmology, 2009
- INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMARetina, 2006